Hospitalization of patients with heart failure. A population-based study

Cowie, Martin R.; Fox, Kevin; Wood, D; Metcalfe, Chris; Thompson, Simon G.; Coats, Andrew J.S.; Poole‐Wilson, P.A.; Sutton, George C.

doi:10.1053/euhj.2001.2973

Cited by 205 publications

(153 citation statements)

References 28 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Just as the study EPICAL and the record OPTIMIZE-HF confirmed the relationship between creatinine and survival, Rassi et al 17 and Cowie et al 20 confirmed the same result, where creatinine was considered an important prognostic factor for survival 17,20,21,25 .…”

Section: Survival Analysissupporting

confidence: 66%

See 1 more Smart Citation

Análise em longo prazo na síndrome coronariana aguda: existem diferenças na morbimortalidade?

Aguiar

Rocha

Esporcatte

et al. 2010

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

Section: Survival Analysissupporting

confidence: 66%

“…Another variable that was considered a predictor of survival by the multivariate model of survival was age, also present in other studies 19,[22][23][24][25] . For each additional ten years of age, the prognosis was worse, with HR: 1.37 and p < 0.001.…”

Section: Survival Analysismentioning

confidence: 93%

Análise em longo prazo na síndrome coronariana aguda: existem diferenças na morbimortalidade?

Aguiar

Rocha

Esporcatte

et al. 2010

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…The baseline characteristics of the current study are similar to population-based cohorts with regard to age and gender ratio and therefore appear to be representative of the general heart failure population. 14,27,28 In epidemiological studies, the median age for patients with heart failure in the community is approximately 75 years, 14,27,28 similar to the present cohort. Patients were, on average, 10 years younger in the CHARM study; only 19% were aged ≥75 years.…”

Section: Discussionsupporting

confidence: 51%

Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect?

Mehta

McDonagh

Phillips

et al. 2009

Clinical Cardiology

View full text Add to dashboard Cite

Background: The addition of the angiotensin II type 1 receptor blocker (ARB) candesartan to a angiotensinconverting enzyme inhibitor (ACEI) has been associated with improved clinical outcomes in patients with heart failure. However many do not tolerate combination therapy and concerns have been raised regarding excessive neurohormonal inhibition. Hypothesis: The majority of patients with chronic heart failure are not eligible or do not tolerate combination therapy with an ACEEI and ARB. Methods: We prospectively evaluated 115 consecutive patients with heart failure (median age 74 y; 74% males; mean left ventricular ejection fraction 30%) within a district general hospital for eligibility and tolerance to combination therapy using candesartan in addition to recommended doses of an ACEI. Results: Overall, 109 (95%) were ineligible to initiate candesartan. The most frequent reasons were that, despite best efforts at optimization, 77% of patients were unable to achieve recommended doses of an ACEI, 29% were relatively asymptomatic, 20% had symptomatic hypotension, and 35% were already taking an ARB due to previous ACEI ''intolerance.'' Overall, 6 (5%) of patients satisfied the eligibility criteria of whom 3 (3% of total) were already taking ''optimal'' doses of an ARB in addition to an ACEI. The remaining 3 patients commenced the titration schedule with candesartan. All 3 patients failed the first titration phase (4 mg once daily) within 2 weeks of initiation, due to the development of hyperkalemia. Conclusions: The use of combination therapy with an ARB in addition to recommended doses of ACEI does not appear feasible in patients with heart failure in the general population, as the vast majority are not eligible.

show abstract

“…The risk of mortality is particularly high in the early period after diagnosis with approximately 25-30% not surviving six months [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Mode of death in patients with newly diagnosed heart failure in the general population

Mehta

Dubrey

McIntyre

et al. 2008

European J of Heart Fail

View full text Add to dashboard Cite

Background: Early prognosis for incident (new) heart failure (HF) patients in the general population is poor. Clinical trials suggest approximately half of chronic HF patients die suddenly but mode of death for incident HF cases in the general population has not been evaluated. Aims: To describe mode of death in the first six months after a new diagnosis in the general population. Methods: Two-centre UK population-based study. Results: 396 incident HF patients were prospectively identified. Overall mortality rates were 6% [3-8%], 11% [8-14%] and 14% [11-18%] at 1, 3 and 6months respectively. There were 59 deaths over a median follow-up of 10months; 86% (n = 51) were cardiovascular (CV) deaths. Overall, the mode of death was progressive HF in 52% (n = 31), sudden death (SD) in 22% (n = 13), other CV death in 12% (n = 7), and non-CV death in 14% (n = 8). On multivariable analysis, progressive HF deaths were associated with older age, lower serum sodium, systolic hypotension, prolonged QRS duration at baseline and absence of ACE inhibitor therapy at the time of discharge or death. Conclusion: Early prognosis after a new diagnosis of HF in the general population is poor and progressive HF, rather than sudden death, accounts for the majority of deaths.

show abstract

Hospitalization of patients with heart failure. A population-based study

Cited by 205 publications

References 28 publications

Análise em longo prazo na síndrome coronariana aguda: existem diferenças na morbimortalidade?

Análise em longo prazo na síndrome coronariana aguda: existem diferenças na morbimortalidade?

Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect?

Mode of death in patients with newly diagnosed heart failure in the general population

Contact Info

Product

Resources

About